However, its pharmacological basis and target mechanisms require further clarification
Participants in the trials noted shifts in liver enzyme counts and fat content through scans
The microbiota can influence host pathophysiology by producing molecules that directly alter metabolism and/or modulate cellular signaling either locally in the gut or systemically via the circulation 1,2
Food and Drug Administration (FDA) to discuss its clinical development program and manufacturing scale-up plans for its lead investigational drug MTX-001, for the treatment of venous leg ulcers
The TV special heralded GLP-1 agonist medications as a miracle tool for many people that could put a dent in Americas obesity epidemic, citing that Nearly one in three Americans are overweight and close to 40 percent qualify as obese. Were seeing double the amount of weight loss you can achieve with this class of medications compared to what weve had in our toolbox for the last several decades, in combination of course with a healthy lifestyle, said Amanda Velazquez, MD, director of obesity medicine at Cedars-Sinai, in the TV special
Boussageon R, Gueyffier F, Cornu C
